摘要
胃癌是上消化道常见的恶性肿瘤之一。对于早期胃癌而言,手术联合化疗效果显著,而对于进展期胃癌(AGC),其效果并不理想。程序性细胞死亡受体1(PD-1)抑制剂的出现为肿瘤治疗提供了全新的理念,研究表明单独使用PD-1抑制剂对AGC疗效有限,与其他疗法的联合治疗会有更大的临床获益。本文基于目前PD-1抑制剂在胃癌中使用的相关研究,对PD-1抑制剂联合其他疗法治疗AGC的研究进展作一综述。
Gastric cancer is one of the most common malignant tumors in the upper digestive tract.For early gastric cancer,the effect of surgery combined with chemotherapy is significant,but for advanced gastric cancer(AGC),the effect is not ideal.The emergence of programmed cell death receptor 1(PD-1)inhibitors provides a new concept for tumor therapy.Studies have shown that PD-1 inhibitors alone have limited efficacy on AGC,and combined therapy with other therapies will have greater clinical benefits.Based on the current research on the application of PD-1 inhibitors in gastric cancer,this paper reviews the research progress of PD-1 inhibitors combined with other therapies in the treatment of AGC.
作者
尚力凝
杜成周
郭刚
陈德合
王杰
陈鹏
李洪涛
Shang Lining;Du Chengzhou;Guo Gang;Chen Dehe;Wang Jie;Chen Peng;Li Hongtao(Graduate School of Ningxia Medical University,Yinchuan 750000,China;Department of General Surgery,the 940 th Hospital of Joint Logistic Support Force of Chinese People’s Liberation Army,Lanzhou 730050,China;The Second Clinical Medical College of Lanzhou University,Lanzhou 730030,China)
出处
《中华普通外科学文献（电子版）》
CAS
2022年第5期376-381,共6页
Chinese Archives of General Surgery(Electronic Edition)
基金
甘肃省科技计划项目(创新基地和人才计划)(21JR1RA186)
科技部、财政部惠民计划项目(2012GS620101)。
关键词
PD-1抑制剂
免疫治疗
进展期胃癌
联合治疗
PD-1 inhibitors
Immunity therapy
Advanced gastric cancer
Combination therapy
